Atrial Fibrillation: U.S. Physician and Payer Perceptions Regarding New Anticoagulants
—A Webinar from Decision Resources
Based on our U.S. Physician & Payer Forum report entitled Pradaxa, Xarelto, and Eliquis for Atrial Fibrillation: How Have Phase III Data Informed Physician and Payer Perceptions of These New Anticoagulants?, Decision Resources is offering this exclusive webinar. Because this presentation will feature major report findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
The drug market for stroke prevention in atrial fibrillation will be fundamentally transformed by the launches and strong uptake of several new oral anticoagulants that are safer and, in some cases, more effective than warfarin. Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) was the first of a wave of new drugs to launch for this indication in October 2010. More recently, Bayer/Janssen’s Xarelto (rivaroxaban) secured FDA approval and Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) captured the limelight with impressive outcomes from its ARISTOTLE trial, in which it showed benefits in efficacy, bleeding and mortality over warfarin.
Decision Resources surveyed 101 U.S. hospital- and office-based non-interventional cardiologists and 20 U.S. managed care organization (MCO) pharmacy directors to assess their attitudes and expectations surrounding current and emerging anticoagulants for atrial fibrillation.
This webinar, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
- What patient share do current antithrombotic drugs, including Pradaxa, enjoy and how does this vary with patients’ levels of stroke risk? What are the factors driving and preventing the use of Pradaxa? Are there differences in drug use, and the forces driving prescription decisions, between hospital- and office-based cardiologists?
- Warfarin has long been the mainstay of stroke prevention treatment in AF but its clinical profile is far from ideal. According to surveyed cardiologists, what proportion of AF patients are intolerant to warfarin and what factors prevent its use in these patients? What proportion of patients discontinue warfarin therapy and why do they do so?
- Given Xarelto’s recent FDA approval for stroke prevention in AF, what are cardiologists’ attitudes towards this brand’s clinical profile relative to warfarin and Pradaxa? What patient share can Xarelto expect and what factors could limit its use? Additionally, to what percentage of their AF patients do cardiologists expect to prescribe Eliquis?
- Across a range of clinical attributes, what are surveyed MCOs’ perceptions of current agents for stroke prevention? What factors drive MCOs’ formulary inclusion decisions? What tiers would MCOs place Xarelto and Eliquis in at different price points, relative to Pradaxa?
Dr. Killeen will conduct a live Q & A session after the presentation.
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Matthew Killeen, Ph.D., is an analyst on the cardiovascular and metabolic disorders team at Decision Resources. Dr. Killeen is an expert on drug safety and has authored a book on cardiac safety and co-chaired a cardiac safety meeting at the FDA. He is also the author of 19 peer-reviewed journal articles on topics including atrial fibrillation, drug safety and ventricular arrhythmias. Prior to joining the company, Dr. Killeen worked in life sciences business development for the London Technology Network and in neuroscience drug discovery at Eli Lilly. Dr. Killeen holds a Ph.D. in Cardiac Electrophysiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds. Additionally, he has held research fellowships at Harvard Medical School and the Massachusetts General Hospital, where he studied the genetic basis of sudden cardiac death.Atrial Fibrillation: U.S. Physician and Payer Perceptions Regarding New Anticoagulants
December 6 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can purchase this report and attend the webinar, please contact us using the information below.
In North America: Keith Rourke | 781-993-2656
In Europe: Kaj van Langendonck | +32-2-357-06-14
In Japan: Makiko Yoshimoto | +81-3-5401-2615
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
